An Overview of the Stability and Delivery Challenges of Commercial Nucleic Acid Therapeutics
Nucleic acid (NA)-based biopharmaceuticals have emerged as promising therapeutic modalities. NA therapeutics are a diverse class of RNA and DNA and include antisense oligonucleotides, siRNA, miRNA, mRNA, small activating RNA, and gene therapies. Meanwhile, NA therapeutics have posed significant stab...
Saved in:
Main Authors: | Rahul G. Ingle (Author), Wei-Jie Fang (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Delivery of nucleic acid therapeutics for cancer immunotherapy
by: Shurong Zhou, et al.
Published: (2020) -
Biosafety assessment of delivery systems for clinical nucleic acid therapeutics
by: Zhimin Li, et al.
Published: (2022) -
Extracellular Vesicles as Delivery Vehicles for Therapeutic Nucleic Acids in Cancer Gene Therapy: Progress and Challenges
by: Rong Du, et al.
Published: (2022) -
Nucleic acid nano-carriers for delivery of antisense and RNAi therapeutics
by: Himanshu Sekhar Panda, et al.
Published: (2024) -
Recent advances in using liposomes for delivery of nucleic acid-based therapeutics
by: Hamdi Nsairat, et al.
Published: (2023)